Myeloma Research News

July 10, 2020July 10, 2020

FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients

Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for hard-to-treat patients with multiple myeloma. The ... Read more

July 1, 2020July 1, 2020

1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects

COVID-19 News, Myeloma Research News

Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 is affecting life for those with this blood cancer. The survey, ... Read more

June 29, 2020June 29, 2020

Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows

COVID-19 News, Myeloma Research News

First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to ... Read more

June 26, 2020June 26, 2020

Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo

COVID-19 News, Myeloma Research News

The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, top-line ... Read more

June 24, 2020June 24, 2020

Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials

Myeloma Research News

Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, according ... Read more

June 22, 2020June 22, 2020

JNJ-4528 Continues to Show Strong, Durable Responses in Trial

Myeloma Research News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating in ... Read more

June 17, 2020June 22, 2020

Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled

Myeloma Research News

A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled, Oncopeptides, the treatment’s developer, announced. The OCEAN trial (NCT03151811) recruited ... Read more

June 15, 2020June 15, 2020

UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo

Myeloma Research News

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or ... Read more

June 12, 2020June 12, 2020

Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients

Myeloma Research News

Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request was ... Read more

June 5, 2020June 5, 2020

New Under-the-skin Darzalex Formulation Approved in EU

Myeloma Research News

The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults with multiple myeloma. The approval of the new type ... Read more

June 3, 2020June 3, 2020

Sarclisa Triple Combo Approved in Europe for Advanced Myeloma Patients

Myeloma Research News

The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma. The approval is specifically for those who have ... Read more

June 1, 2020June 1, 2020

CHMP Favors EU Approval of Darzalex Faspro as Faster Injection Therapy for Myeloma

Myeloma Research News

Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the ... Read more

May 18, 2020May 18, 2020

FDA Asks for More Data on Ide-cel as Potential Multiple Myeloma Therapy

Myeloma Research News

The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a request to approve their lead CAR T-cell therapy — idecabtagene vicleucel ... Read more

May 11, 2020May 11, 2020

Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment

Myeloma Research News

A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with multiple myeloma, a study suggests. Its ... Read more

May 5, 2020May 5, 2020

FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma

Myeloma Research News

The U.S. Food and Drug Administration (FDA) approved Janssen‘s new formulation of daratumumab — a subcutaneous or under-the-skin injection treatment called Darzalex Faspro (daratumumab and hyaluronidase) — as a faster and easier ... Read more